Company: GRCE
Filing Date: 2025-07-28
Form Type: DEF 14A
Source: 0001140361-25-027456
Chunk: 6

Company: Grace Therapeutics, Inc.
Filing Date: 2025-07-28
Form: DEF 14A
Chunk 6
---
 Withholding a vote from a director nominee will not be voted with respect to the director nominee indicated and will have no impact on the election of directors, although it will be counted for purposes of establishing a quorum. Broker non-votes will have no effect on the outcome of Proposal No. 1. |

For Proposal No. 2, to approve, on an advisory basis, the compensation of our named executive officers, the affirmative vote of the majority of votes cast on this Proposal is required for approval. Abstentions and broker non-votes will be considered in determining whether a quorum is present and will have no effect on the outcome of Proposal 2. For Proposal No. 3, to ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending March 31, 2026, the affirmative vote of the majority of votes cast on this Proposal is required for approval. Abstentions will have no effect on the outcome of Proposal No. 3. There will be no broker non-votes with respect to Proposal No. 3.

| Q: | What does it mean to vote by proxy? |

| A: | A proxy is a person you appoint to vote on your behalf. Unless you vote during the Annual Meeting, by voting using any of the other methods described in this Proxy Statement, you will be appointing as your proxies Prashant Kohli, our Chief Executive Officer, and Robert DelAversano, our Principal Financial Officer and Vice President, Finance. They may act together or individually on your behalf, and will have the authority to appoint a substitute to act as proxy. Whether or not you expect to attend the Annual Meeting, we request that you please use the means available to you to vote by proxy so as to ensure that your shares of common stock may be voted. |

| Q: | What are the recommendations of the Board? |

| A: | Our Board unanimously recommends that you vote your shares as follows: |

| • | “FOR ALL” for the election of each of the five director nominees to our Board for a one-year term expiring at the 2026 Annual Meeting; |

| • | “FOR” approval, on an advisory basis, of the compensation of our named executive officers; and |

| Q: | What if another matter is properly brought before the Annual Meeting? |

| A: | Our Board knows of no other matters that will be presented for consideration at the Annual Meeting. If any other matters are properly brought